Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

60.99 +0.97 (+1.62%)
Official Closing Price Updated: 4:10 PM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,615,956
Open 59.80
Bid (Size) 60.90 (1)
Ask (Size) 60.95 (1)
Prev. Close 60.02
Today's Range 59.37 - 61.64
52wk Range 39.35 - 63.33
Shares Outstanding 2,222,113,553
Dividend Yield 3.94%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday. 
Via Chartmill
5 Ways to Prepare for AI’s ‘Tower of Terror’ Moment
As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025. 
Via InvestorPlace
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Interest Rates Political

Performance

YTD
+7.4%
+7.4%
1 Month
+2.3%
+2.3%
3 Month
+8.8%
+8.8%
6 Month
+17.9%
+17.9%
1 Year
+15.1%
+15.1%

More News

Read More
50-Year-Old Early Retiree Making $175,000 in Dividends Shares Portfolio - 'Now I Spend on Travel, Cars and Doing What I Want'
Via Benzinga
Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
From Bristol Myers Squibb
Via Business Wire
The 5-Letter Word Every Investor Should Memorize to Win in 2025
Via InvestorPlace
Topics Economy World Trade
Exposures Economy Tariff
3 Deeply Discounted Dividend Stocks to Buy Today
Via The Motley Fool
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
Via FinancialNewsMedia
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors
Via Benzinga
Exposures Product Safety
1 Large-Cap Stock on Our Watchlist and 2 to Brush Off
Via StockStory
Topics Retirement
Exposures Pension
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
BRISTOL-MYERS SQUIBB CO (NYSE:BMY): good value for what you're paying.
Via Chartmill
The Stock Market Hates Uncertainty & Loves To Climb A Wall-Of-Worry
Via Talk Markets
Topics ETFs Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
Via Benzinga
2 High-Yield Dividend Stocks That Are Bargain Buys Right Now
Via The Motley Fool
Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) suited for dividend investing?
Via Chartmill
Friday's session: top gainers and losers in the S&P500 index
Via Chartmill
Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer
Via Benzinga
These S&P500 stocks are gapping in today's session
Via Chartmill
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
Via Benzinga
Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb Co Chart Analysis
Via Talk Markets
Topics Stocks / Equities

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 60.99
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 03/31/25 04:10 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 135.53B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 136B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.